Nevena Damjanov

Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial

Andrew X. Zhu, Richard S. Finn, Julien Edeline et al. · The Lancet Oncology · 2018 · 2.5K citations

Medicine, Oncology, Pharmacology +11

Derazantinib (ARQ 087) in advanced or inoperable FGFR2 gene fusion-positive intrahepatic cholangiocarcinoma

Vincenzo Mazzaferro, Bassel F. El‐Rayes, Michele Droz Dit Busset et al. · British Journal of Cancer · 2018 · 380 citations · Full text

Medicine, Oncology, Pharmacology +17

Tivantinib for second-line treatment of MET-high, advanced hepatocellular carcinoma (METIV-HCC): a final analysis of a phase 3, randomised, placebo-controlled study

Lorenza Rimassa, Eric Assénat, Markus Peck‐Radosavljevic et al. · The Lancet Oncology · 2018 · 349 citations

Medicine, Oncology, Pharmacology +11

Barriers to Clinical Trial Participation as Perceived by Oncologists and Patients

Neal J. Meropol, Joanne S. Buzaglo, Jennifer Millard et al. · Journal of the National Comprehensive Cancer Network · 2007 · 141 citations

Medicine, Clinical Sciences, Oncology +14

Randomized Phase II Multicenter Trial of Two Schedules of Lapatinib as First- or Second-Line Monotherapy in Patients with Advanced or Metastatic Non–Small Cell Lung Cancer

Helen J. Ross, George R. Blumenschein, Joseph Aisner et al. · Clinical Cancer Research · 2010 · 119 citations

Medicine, Oncology, Pharmacology +17